Chen C, Lokhandwala M F
Department of Pharmacology, College of Pharmacy, University of Houston, Texas 77204-5515.
Naunyn Schmiedebergs Arch Pharmacol. 1993 Mar;347(3):289-95. doi: 10.1007/BF00167447.
Endogenous kidney dopamine (DA) causes natriuresis and diuresis, at least partly, via inhibition of proximal tubular Na+,K(+)-ATPase. The present study was done to identify the dopamine receptor subtype(s) involved in dopamine-induced inhibition of Na+,K(+)-ATPase activity. Suspensions of renal proximal tubules from Sprague-Dawley rats were incubated with dopamine, the DA-1 receptor agonist fenoldopam or the DA-2 receptor agonist SK&F 89124 in the presence or absence of either the DA-1 receptor antagonist SCH 23390 or the DA-2 receptor antagonist domperidone. Dopamine and fenoldopam (10(-5) to 10(-8) mol/l) produced a concentration-dependent inhibition of Na+,K(+)-ATPase activity. However, SK&F 89124 failed to produce any significant effect over the same concentration range. Incubation with fenoldopam (10(-5) to 10(-8) mol/l) in the presence of SK&F 89124 (10(-6) mol/l) inhibited Na+,K(+)-ATPase activity to a degree similar to that with fenoldopam alone. Furthermore, DA-induced inhibition of Na+,K(+)-ATPase activity was attenuated by SCH 23390, but not by domperidone. Since alpha-adrenoceptor activation is reported to stimulate Na+,K(+)-ATPase activity and, at higher concentrations, dopamine also acts as an alpha-adrenoceptor agonist, the potential opposing effect from alpha-adrenoceptor activation on DA-induced inhibition of Na+,K(+)-ATPase activity was investigated by using the alpha-adrenoceptor blocker phentolamine. We found that, in the lower concentration range (10(-5) to 10(-7) mol/l), dopamine-induced inhibition of Na+,K(+)-ATPase activity in the presence of phentolamine was similar in magnitude to that observed with dopamine alone.(ABSTRACT TRUNCATED AT 250 WORDS)
内源性肾脏多巴胺(DA)至少部分地通过抑制近端肾小管钠钾ATP酶引起利钠和利尿作用。本研究旨在确定参与多巴胺诱导的钠钾ATP酶活性抑制的多巴胺受体亚型。将来自Sprague-Dawley大鼠的肾近端小管悬浮液与多巴胺、DA-1受体激动剂非诺多泮或DA-2受体激动剂SK&F 89124一起孵育,同时存在或不存在DA-1受体拮抗剂SCH 23390或DA-2受体拮抗剂多潘立酮。多巴胺和非诺多泮(10^-5至10^-8摩尔/升)对钠钾ATP酶活性产生浓度依赖性抑制。然而,在相同浓度范围内,SK&F 89124未能产生任何显著影响。在SK&F 89124(10^-6摩尔/升)存在下与非诺多泮(10^-5至10^-8摩尔/升)一起孵育,钠钾ATP酶活性的抑制程度与单独使用非诺多泮时相似。此外,多巴胺诱导的钠钾ATP酶活性抑制被SCH 23390减弱,但未被多潘立酮减弱。由于据报道α-肾上腺素能受体激活会刺激钠钾ATP酶活性,并且在较高浓度下多巴胺也作为α-肾上腺素能受体激动剂起作用,因此使用α-肾上腺素能受体阻滞剂酚妥拉明研究了α-肾上腺素能受体激活对多巴胺诱导的钠钾ATP酶活性抑制的潜在相反作用。我们发现,在较低浓度范围(10^-5至10^-7摩尔/升)内,在酚妥拉明存在下多巴胺诱导的钠钾ATP酶活性抑制程度与单独观察到的多巴胺抑制程度相似。(摘要截断于250字)